ERBB2 and neoplasm: The impacts of ERBB2 amplification on tumour growth have been detected in several solid tumours, in particular in breast cancer (BC) where the use of trastuzumab and other monoclonal antibodies, drug conjugated antibodies or tyrosine kinase inhibitors (TKi) have revolutionised the natural history of patients with advanced and locoregional disease.